Know Cancer

or
forgot password

Development of a Quantitative Tissue Optical Index of Breast Density


N/A
21 Years
45 Years
Open (Enrolling by invite only)
Female
Breast Cancer

Thank you

Trial Information

Development of a Quantitative Tissue Optical Index of Breast Density


The researcher wants to study pre-menopausal patients with hormonal positive breast cancer,
taking tamoxifen to reduce the risk of recurrence. Diffuse optical spectroscopic imaging can
captures breast density functional changes measured by MRI and mammography. The DOSI can
prove the underlying physiological origin of breast density variations and provide detail
functional index suitable for bedside assessment of tamoxifen therapy response.The role of
breast density can predict and establish, this information can help individual women decide
whether to start or continue tamoxifen therapy based on their own risk vs. benefit
assessment.


Inclusion Criteria:



- Pre-Menopausal Women with diagnosis of breast cancer and taking Tamoxifen

Exclusion Criteria:

- Pre-Menopausal Women with diagnosis of breast cancer NOT taking Tamoxifen

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Outcome Measure:

Breast Density

Outcome Description:

Breast Density

Outcome Time Frame:

up to 12 months

Safety Issue:

No

Principal Investigator

Thomas O' Sullivan, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Laser Institute, UCI

Authority:

United States: Institutional Review Board

Study ID:

DOD BC120040

NCT ID:

NCT01773551

Start Date:

April 2012

Completion Date:

April 2016

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Beckman Laser Institute Medical clinicIrvine, California  92612